Considering inhibition of DPP-IV has been demonstrated to increase concentrations of intact GLP-1 2–3 fold in patients with type 2 diabetes [3], it is conceivable that sitagliptin, a potent and highly selective DPP-IV inhibitor, improves endothelial dysfunction as a result. This evidence concerns the gene GLP1R and endothelial dysfunction.